WillowV1, Main, Corpus, bibRecord, 000701

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Identifieur interne : 000701 ( Main/Corpus ); précédent : 000700; suivant : 000702

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Auteurs : Anthony R. Mato ; Meghan Thompson ; John N. Allan ; Danielle M. Brander ; John M. Pagel ; Chaitra S. Ujjani ; Brian T. Hill ; Nicole Lamanna ; Frederick Lansigan ; Ryan Jacobs ; Mazyar Shadman ; Alan P. Skarbnik ; Jeffrey J. Pu ; Paul M. Barr ; Alison R. Sehgal ; Bruce D. Cheson ; Clive S. Zent ; Hande H. Tuncer ; Stephen J. Schuster ; Peter V. Pickens ; Nirav N. Shah ; Andre Goy ; Allison M. Winter ; Christine Garcia ; Kaitlin Kennard ; Krista Isaac ; Colleen Dorsey ; Lisa M. Gashonia ; Arun K. Singavi ; Lindsey E. Roeker ; Andrew Zelenetz ; Annalynn Williams ; Christina Howlett ; Hanna Weissbrot ; Naveed Ali ; Sirin Khajavian ; Andrea Sitlinger ; Eve Tranchito ; Joanna Rhodes ; Joshua Felsenfeld ; Neil Bailey ; Bhavisha Patel ; Timothy F. Burns ; Melissa Yacur ; Mansi Malhotra ; Jakub Svoboda ; Richard R. Furman ; Chadi Nabhan

Source :

Haematologica [ 1592-8721 ] ; 2018.

RBID : pubmed:29880613

English descriptors

KwdEn :
- Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Antineoplastic Agents (administration & dosage), Antineoplastic Agents (adverse effects), Antineoplastic Agents (therapeutic use), Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Bridged Bicyclo Compounds, Heterocyclic (administration & dosage), Bridged Bicyclo Compounds, Heterocyclic (adverse effects), Bridged Bicyclo Compounds, Heterocyclic (therapeutic use), Disease Management (MeSH), Drug Resistance, Neoplasm (MeSH), Female (MeSH), Humans (MeSH), Leukemia, Lymphocytic, Chronic, B-Cell (diagnosis), Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy), Leukemia, Lymphocytic, Chronic, B-Cell (genetics), Leukemia, Lymphocytic, Chronic, B-Cell (mortality), Male (MeSH), Middle Aged (MeSH), Recurrence (MeSH), Sulfonamides (administration & dosage), Sulfonamides (adverse effects), Sulfonamides (therapeutic use), Survival Analysis (MeSH), Treatment Outcome (MeSH), Tumor Lysis Syndrome (etiology).
MESH :
- chemical , administration & dosage : Antineoplastic Agents, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides.
- chemical , adverse effects : Antineoplastic Agents, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides.
- chemical , therapeutic use : Antineoplastic Agents, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- diagnosis : Leukemia, Lymphocytic, Chronic, B-Cell.
- drug therapy : Leukemia, Lymphocytic, Chronic, B-Cell.
- etiology : Tumor Lysis Syndrome.
- genetics : Leukemia, Lymphocytic, Chronic, B-Cell.
- mortality : Leukemia, Lymphocytic, Chronic, B-Cell.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Aged, Aged, 80 and over, Disease Management, Drug Resistance, Neoplasm, Female, Humans, Male, Middle Aged, Recurrence, Survival Analysis, Treatment Outcome.

Abstract

Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia treated with venetoclax to describe outcomes, toxicities, and treatment selection following venetoclax discontinuation. A total of 141 chronic lymphocytic leukemia patients were included (98% relapsed/refractory). Median age at venetoclax initiation was 67 years (range 37-91), median prior therapies was 3 (0-11), 81% unmutated IGHV, 45% del(17p), and 26.8% complex karyotype (≥ 3 abnormalities). Prior to venetoclax initiation, 89% received a B-cell receptor antagonist. For tumor lysis syndrome prophylaxis, 93% received allopurinol, 92% normal saline, and 45% rasburicase. Dose escalation to the maximum recommended dose of 400 mg daily was achieved in 85% of patients. Adverse events of interest included neutropenia in 47.4%, thrombocytopenia in 36%, tumor lysis syndrome in 13.4%, neutropenic fever in 11.6%, and diarrhea in 7.3%. The overall response rate to venetoclax was 72% (19.4% complete remission). With a median follow up of 7 months, median progression free survival and overall survival for the entire cohort have not been reached. To date, 41 venetoclax treated patients have discontinued therapy and 24 have received a subsequent therapy, most commonly ibrutinib. In the largest clinical experience of venetoclax-treated chronic lymphocytic leukemia patients, the majority successfully completed and maintained a maximum recommended dose. Response rates and duration of response appear comparable to clinical trial data. Venetoclax was active in patients with mutations known to confer ibrutinib resistance. Optimal sequencing of newer chronic lymphocytic leukemia therapies requires further study.

DOI: 10.3324/haematol.2018.193615
PubMed: 29880613
PubMed Central: PMC6119152

Links to Exploration step

pubmed:29880613

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.</title>
<author><name sortKey="Mato, Anthony R" sort="Mato, Anthony R" uniqKey="Mato A" first="Anthony R" last="Mato">Anthony R. Mato</name>
<affiliation><nlm:affiliation>CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA matoa@mskcc.org.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Thompson, Meghan" sort="Thompson, Meghan" uniqKey="Thompson M" first="Meghan" last="Thompson">Meghan Thompson</name>
<affiliation><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Allan, John N" sort="Allan, John N" uniqKey="Allan J" first="John N" last="Allan">John N. Allan</name>
<affiliation><nlm:affiliation>New York Presbyterian & Weill Cornell, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Brander, Danielle M" sort="Brander, Danielle M" uniqKey="Brander D" first="Danielle M" last="Brander">Danielle M. Brander</name>
<affiliation><nlm:affiliation>Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pagel, John M" sort="Pagel, John M" uniqKey="Pagel J" first="John M" last="Pagel">John M. Pagel</name>
<affiliation><nlm:affiliation>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ujjani, Chaitra S" sort="Ujjani, Chaitra S" uniqKey="Ujjani C" first="Chaitra S" last="Ujjani">Chaitra S. Ujjani</name>
<affiliation><nlm:affiliation>Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hill, Brian T" sort="Hill, Brian T" uniqKey="Hill B" first="Brian T" last="Hill">Brian T. Hill</name>
<affiliation><nlm:affiliation>Taussig Cancer Institute, Cleveland Clinic Foundation, OH, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lamanna, Nicole" sort="Lamanna, Nicole" uniqKey="Lamanna N" first="Nicole" last="Lamanna">Nicole Lamanna</name>
<affiliation><nlm:affiliation>Columbia University Medical Center, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lansigan, Frederick" sort="Lansigan, Frederick" uniqKey="Lansigan F" first="Frederick" last="Lansigan">Frederick Lansigan</name>
<affiliation><nlm:affiliation>Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Jacobs, Ryan" sort="Jacobs, Ryan" uniqKey="Jacobs R" first="Ryan" last="Jacobs">Ryan Jacobs</name>
<affiliation><nlm:affiliation>Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Shadman, Mazyar" sort="Shadman, Mazyar" uniqKey="Shadman M" first="Mazyar" last="Shadman">Mazyar Shadman</name>
<affiliation><nlm:affiliation>University of Washington/Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, WA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Skarbnik, Alan P" sort="Skarbnik, Alan P" uniqKey="Skarbnik A" first="Alan P" last="Skarbnik">Alan P. Skarbnik</name>
<affiliation><nlm:affiliation>John Theurer Cancer Center, Hackensack Meridian Health, NJ, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pu, Jeffrey J" sort="Pu, Jeffrey J" uniqKey="Pu J" first="Jeffrey J" last="Pu">Jeffrey J. Pu</name>
<affiliation><nlm:affiliation>Penn State Health, Hershey, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Barr, Paul M" sort="Barr, Paul M" uniqKey="Barr P" first="Paul M" last="Barr">Paul M. Barr</name>
<affiliation><nlm:affiliation>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sehgal, Alison R" sort="Sehgal, Alison R" uniqKey="Sehgal A" first="Alison R" last="Sehgal">Alison R. Sehgal</name>
<affiliation><nlm:affiliation>University of Pittsburgh Medical Center, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cheson, Bruce D" sort="Cheson, Bruce D" uniqKey="Cheson B" first="Bruce D" last="Cheson">Bruce D. Cheson</name>
<affiliation><nlm:affiliation>Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zent, Clive S" sort="Zent, Clive S" uniqKey="Zent C" first="Clive S" last="Zent">Clive S. Zent</name>
<affiliation><nlm:affiliation>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tuncer, Hande H" sort="Tuncer, Hande H" uniqKey="Tuncer H" first="Hande H" last="Tuncer">Hande H. Tuncer</name>
<affiliation><nlm:affiliation>Tufts Medical Center, Boston, MA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Schuster, Stephen J" sort="Schuster, Stephen J" uniqKey="Schuster S" first="Stephen J" last="Schuster">Stephen J. Schuster</name>
<affiliation><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pickens, Peter V" sort="Pickens, Peter V" uniqKey="Pickens P" first="Peter V" last="Pickens">Peter V. Pickens</name>
<affiliation><nlm:affiliation>Abington Hem. Onc. Assoc., Inc., Willow Grove, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Shah, Nirav N" sort="Shah, Nirav N" uniqKey="Shah N" first="Nirav N" last="Shah">Nirav N. Shah</name>
<affiliation><nlm:affiliation>Division of Hematology & Oncology, Medical College of Wisconsin, Brookfield, WI, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Goy, Andre" sort="Goy, Andre" uniqKey="Goy A" first="Andre" last="Goy">Andre Goy</name>
<affiliation><nlm:affiliation>John Theurer Cancer Center, Hackensack Meridian Health, NJ, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Winter, Allison M" sort="Winter, Allison M" uniqKey="Winter A" first="Allison M" last="Winter">Allison M. Winter</name>
<affiliation><nlm:affiliation>Taussig Cancer Institute, Cleveland Clinic Foundation, OH, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Garcia, Christine" sort="Garcia, Christine" uniqKey="Garcia C" first="Christine" last="Garcia">Christine Garcia</name>
<affiliation><nlm:affiliation>University of Pittsburgh Medical Center, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kennard, Kaitlin" sort="Kennard, Kaitlin" uniqKey="Kennard K" first="Kaitlin" last="Kennard">Kaitlin Kennard</name>
<affiliation><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Isaac, Krista" sort="Isaac, Krista" uniqKey="Isaac K" first="Krista" last="Isaac">Krista Isaac</name>
<affiliation><nlm:affiliation>Internal Medicine, Lankenau Medical Center, Wynnewood, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dorsey, Colleen" sort="Dorsey, Colleen" uniqKey="Dorsey C" first="Colleen" last="Dorsey">Colleen Dorsey</name>
<affiliation><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gashonia, Lisa M" sort="Gashonia, Lisa M" uniqKey="Gashonia L" first="Lisa M" last="Gashonia">Lisa M. Gashonia</name>
<affiliation><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Singavi, Arun K" sort="Singavi, Arun K" uniqKey="Singavi A" first="Arun K" last="Singavi">Arun K. Singavi</name>
<affiliation><nlm:affiliation>Division of Hematology & Oncology, Medical College of Wisconsin, Brookfield, WI, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Roeker, Lindsey E" sort="Roeker, Lindsey E" uniqKey="Roeker L" first="Lindsey E" last="Roeker">Lindsey E. Roeker</name>
<affiliation><nlm:affiliation>CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zelenetz, Andrew" sort="Zelenetz, Andrew" uniqKey="Zelenetz A" first="Andrew" last="Zelenetz">Andrew Zelenetz</name>
<affiliation><nlm:affiliation>CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Williams, Annalynn" sort="Williams, Annalynn" uniqKey="Williams A" first="Annalynn" last="Williams">Annalynn Williams</name>
<affiliation><nlm:affiliation>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Howlett, Christina" sort="Howlett, Christina" uniqKey="Howlett C" first="Christina" last="Howlett">Christina Howlett</name>
<affiliation><nlm:affiliation>John Theurer Cancer Center, Hackensack Meridian Health, NJ, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Weissbrot, Hanna" sort="Weissbrot, Hanna" uniqKey="Weissbrot H" first="Hanna" last="Weissbrot">Hanna Weissbrot</name>
<affiliation><nlm:affiliation>Columbia University Medical Center, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ali, Naveed" sort="Ali, Naveed" uniqKey="Ali N" first="Naveed" last="Ali">Naveed Ali</name>
<affiliation><nlm:affiliation>Abington Hem. Onc. Assoc., Inc., Willow Grove, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Khajavian, Sirin" sort="Khajavian, Sirin" uniqKey="Khajavian S" first="Sirin" last="Khajavian">Sirin Khajavian</name>
<affiliation><nlm:affiliation>University of Washington/Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, WA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sitlinger, Andrea" sort="Sitlinger, Andrea" uniqKey="Sitlinger A" first="Andrea" last="Sitlinger">Andrea Sitlinger</name>
<affiliation><nlm:affiliation>Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tranchito, Eve" sort="Tranchito, Eve" uniqKey="Tranchito E" first="Eve" last="Tranchito">Eve Tranchito</name>
<affiliation><nlm:affiliation>Taussig Cancer Institute, Cleveland Clinic Foundation, OH, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Rhodes, Joanna" sort="Rhodes, Joanna" uniqKey="Rhodes J" first="Joanna" last="Rhodes">Joanna Rhodes</name>
<affiliation><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Felsenfeld, Joshua" sort="Felsenfeld, Joshua" uniqKey="Felsenfeld J" first="Joshua" last="Felsenfeld">Joshua Felsenfeld</name>
<affiliation><nlm:affiliation>New York Presbyterian & Weill Cornell, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bailey, Neil" sort="Bailey, Neil" uniqKey="Bailey N" first="Neil" last="Bailey">Neil Bailey</name>
<affiliation><nlm:affiliation>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Patel, Bhavisha" sort="Patel, Bhavisha" uniqKey="Patel B" first="Bhavisha" last="Patel">Bhavisha Patel</name>
<affiliation><nlm:affiliation>Washington Hospital Center, DC, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Burns, Timothy F" sort="Burns, Timothy F" uniqKey="Burns T" first="Timothy F" last="Burns">Timothy F. Burns</name>
<affiliation><nlm:affiliation>Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Yacur, Melissa" sort="Yacur, Melissa" uniqKey="Yacur M" first="Melissa" last="Yacur">Melissa Yacur</name>
<affiliation><nlm:affiliation>Penn State Health, Hershey, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Malhotra, Mansi" sort="Malhotra, Mansi" uniqKey="Malhotra M" first="Mansi" last="Malhotra">Mansi Malhotra</name>
<affiliation><nlm:affiliation>Tufts Medical Center, Boston, MA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Svoboda, Jakub" sort="Svoboda, Jakub" uniqKey="Svoboda J" first="Jakub" last="Svoboda">Jakub Svoboda</name>
<affiliation><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Furman, Richard R" sort="Furman, Richard R" uniqKey="Furman R" first="Richard R" last="Furman">Richard R. Furman</name>
<affiliation><nlm:affiliation>New York Presbyterian & Weill Cornell, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Nabhan, Chadi" sort="Nabhan, Chadi" uniqKey="Nabhan C" first="Chadi" last="Nabhan">Chadi Nabhan</name>
<affiliation><nlm:affiliation>Cardinal Health, Dublin, OH, USA.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:29880613</idno>
<idno type="pmid">29880613</idno>
<idno type="doi">10.3324/haematol.2018.193615</idno>
<idno type="pmc">PMC6119152</idno>
<idno type="wicri:Area/Main/Corpus">000701</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000701</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.</title>
<author><name sortKey="Mato, Anthony R" sort="Mato, Anthony R" uniqKey="Mato A" first="Anthony R" last="Mato">Anthony R. Mato</name>
<affiliation><nlm:affiliation>CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA matoa@mskcc.org.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Thompson, Meghan" sort="Thompson, Meghan" uniqKey="Thompson M" first="Meghan" last="Thompson">Meghan Thompson</name>
<affiliation><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Allan, John N" sort="Allan, John N" uniqKey="Allan J" first="John N" last="Allan">John N. Allan</name>
<affiliation><nlm:affiliation>New York Presbyterian & Weill Cornell, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Brander, Danielle M" sort="Brander, Danielle M" uniqKey="Brander D" first="Danielle M" last="Brander">Danielle M. Brander</name>
<affiliation><nlm:affiliation>Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pagel, John M" sort="Pagel, John M" uniqKey="Pagel J" first="John M" last="Pagel">John M. Pagel</name>
<affiliation><nlm:affiliation>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ujjani, Chaitra S" sort="Ujjani, Chaitra S" uniqKey="Ujjani C" first="Chaitra S" last="Ujjani">Chaitra S. Ujjani</name>
<affiliation><nlm:affiliation>Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hill, Brian T" sort="Hill, Brian T" uniqKey="Hill B" first="Brian T" last="Hill">Brian T. Hill</name>
<affiliation><nlm:affiliation>Taussig Cancer Institute, Cleveland Clinic Foundation, OH, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lamanna, Nicole" sort="Lamanna, Nicole" uniqKey="Lamanna N" first="Nicole" last="Lamanna">Nicole Lamanna</name>
<affiliation><nlm:affiliation>Columbia University Medical Center, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lansigan, Frederick" sort="Lansigan, Frederick" uniqKey="Lansigan F" first="Frederick" last="Lansigan">Frederick Lansigan</name>
<affiliation><nlm:affiliation>Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Jacobs, Ryan" sort="Jacobs, Ryan" uniqKey="Jacobs R" first="Ryan" last="Jacobs">Ryan Jacobs</name>
<affiliation><nlm:affiliation>Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Shadman, Mazyar" sort="Shadman, Mazyar" uniqKey="Shadman M" first="Mazyar" last="Shadman">Mazyar Shadman</name>
<affiliation><nlm:affiliation>University of Washington/Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, WA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Skarbnik, Alan P" sort="Skarbnik, Alan P" uniqKey="Skarbnik A" first="Alan P" last="Skarbnik">Alan P. Skarbnik</name>
<affiliation><nlm:affiliation>John Theurer Cancer Center, Hackensack Meridian Health, NJ, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pu, Jeffrey J" sort="Pu, Jeffrey J" uniqKey="Pu J" first="Jeffrey J" last="Pu">Jeffrey J. Pu</name>
<affiliation><nlm:affiliation>Penn State Health, Hershey, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Barr, Paul M" sort="Barr, Paul M" uniqKey="Barr P" first="Paul M" last="Barr">Paul M. Barr</name>
<affiliation><nlm:affiliation>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sehgal, Alison R" sort="Sehgal, Alison R" uniqKey="Sehgal A" first="Alison R" last="Sehgal">Alison R. Sehgal</name>
<affiliation><nlm:affiliation>University of Pittsburgh Medical Center, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cheson, Bruce D" sort="Cheson, Bruce D" uniqKey="Cheson B" first="Bruce D" last="Cheson">Bruce D. Cheson</name>
<affiliation><nlm:affiliation>Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zent, Clive S" sort="Zent, Clive S" uniqKey="Zent C" first="Clive S" last="Zent">Clive S. Zent</name>
<affiliation><nlm:affiliation>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tuncer, Hande H" sort="Tuncer, Hande H" uniqKey="Tuncer H" first="Hande H" last="Tuncer">Hande H. Tuncer</name>
<affiliation><nlm:affiliation>Tufts Medical Center, Boston, MA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Schuster, Stephen J" sort="Schuster, Stephen J" uniqKey="Schuster S" first="Stephen J" last="Schuster">Stephen J. Schuster</name>
<affiliation><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pickens, Peter V" sort="Pickens, Peter V" uniqKey="Pickens P" first="Peter V" last="Pickens">Peter V. Pickens</name>
<affiliation><nlm:affiliation>Abington Hem. Onc. Assoc., Inc., Willow Grove, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Shah, Nirav N" sort="Shah, Nirav N" uniqKey="Shah N" first="Nirav N" last="Shah">Nirav N. Shah</name>
<affiliation><nlm:affiliation>Division of Hematology & Oncology, Medical College of Wisconsin, Brookfield, WI, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Goy, Andre" sort="Goy, Andre" uniqKey="Goy A" first="Andre" last="Goy">Andre Goy</name>
<affiliation><nlm:affiliation>John Theurer Cancer Center, Hackensack Meridian Health, NJ, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Winter, Allison M" sort="Winter, Allison M" uniqKey="Winter A" first="Allison M" last="Winter">Allison M. Winter</name>
<affiliation><nlm:affiliation>Taussig Cancer Institute, Cleveland Clinic Foundation, OH, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Garcia, Christine" sort="Garcia, Christine" uniqKey="Garcia C" first="Christine" last="Garcia">Christine Garcia</name>
<affiliation><nlm:affiliation>University of Pittsburgh Medical Center, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kennard, Kaitlin" sort="Kennard, Kaitlin" uniqKey="Kennard K" first="Kaitlin" last="Kennard">Kaitlin Kennard</name>
<affiliation><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Isaac, Krista" sort="Isaac, Krista" uniqKey="Isaac K" first="Krista" last="Isaac">Krista Isaac</name>
<affiliation><nlm:affiliation>Internal Medicine, Lankenau Medical Center, Wynnewood, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dorsey, Colleen" sort="Dorsey, Colleen" uniqKey="Dorsey C" first="Colleen" last="Dorsey">Colleen Dorsey</name>
<affiliation><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gashonia, Lisa M" sort="Gashonia, Lisa M" uniqKey="Gashonia L" first="Lisa M" last="Gashonia">Lisa M. Gashonia</name>
<affiliation><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Singavi, Arun K" sort="Singavi, Arun K" uniqKey="Singavi A" first="Arun K" last="Singavi">Arun K. Singavi</name>
<affiliation><nlm:affiliation>Division of Hematology & Oncology, Medical College of Wisconsin, Brookfield, WI, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Roeker, Lindsey E" sort="Roeker, Lindsey E" uniqKey="Roeker L" first="Lindsey E" last="Roeker">Lindsey E. Roeker</name>
<affiliation><nlm:affiliation>CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zelenetz, Andrew" sort="Zelenetz, Andrew" uniqKey="Zelenetz A" first="Andrew" last="Zelenetz">Andrew Zelenetz</name>
<affiliation><nlm:affiliation>CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Williams, Annalynn" sort="Williams, Annalynn" uniqKey="Williams A" first="Annalynn" last="Williams">Annalynn Williams</name>
<affiliation><nlm:affiliation>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Howlett, Christina" sort="Howlett, Christina" uniqKey="Howlett C" first="Christina" last="Howlett">Christina Howlett</name>
<affiliation><nlm:affiliation>John Theurer Cancer Center, Hackensack Meridian Health, NJ, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Weissbrot, Hanna" sort="Weissbrot, Hanna" uniqKey="Weissbrot H" first="Hanna" last="Weissbrot">Hanna Weissbrot</name>
<affiliation><nlm:affiliation>Columbia University Medical Center, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ali, Naveed" sort="Ali, Naveed" uniqKey="Ali N" first="Naveed" last="Ali">Naveed Ali</name>
<affiliation><nlm:affiliation>Abington Hem. Onc. Assoc., Inc., Willow Grove, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Khajavian, Sirin" sort="Khajavian, Sirin" uniqKey="Khajavian S" first="Sirin" last="Khajavian">Sirin Khajavian</name>
<affiliation><nlm:affiliation>University of Washington/Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, WA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sitlinger, Andrea" sort="Sitlinger, Andrea" uniqKey="Sitlinger A" first="Andrea" last="Sitlinger">Andrea Sitlinger</name>
<affiliation><nlm:affiliation>Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tranchito, Eve" sort="Tranchito, Eve" uniqKey="Tranchito E" first="Eve" last="Tranchito">Eve Tranchito</name>
<affiliation><nlm:affiliation>Taussig Cancer Institute, Cleveland Clinic Foundation, OH, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Rhodes, Joanna" sort="Rhodes, Joanna" uniqKey="Rhodes J" first="Joanna" last="Rhodes">Joanna Rhodes</name>
<affiliation><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Felsenfeld, Joshua" sort="Felsenfeld, Joshua" uniqKey="Felsenfeld J" first="Joshua" last="Felsenfeld">Joshua Felsenfeld</name>
<affiliation><nlm:affiliation>New York Presbyterian & Weill Cornell, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bailey, Neil" sort="Bailey, Neil" uniqKey="Bailey N" first="Neil" last="Bailey">Neil Bailey</name>
<affiliation><nlm:affiliation>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Patel, Bhavisha" sort="Patel, Bhavisha" uniqKey="Patel B" first="Bhavisha" last="Patel">Bhavisha Patel</name>
<affiliation><nlm:affiliation>Washington Hospital Center, DC, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Burns, Timothy F" sort="Burns, Timothy F" uniqKey="Burns T" first="Timothy F" last="Burns">Timothy F. Burns</name>
<affiliation><nlm:affiliation>Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Yacur, Melissa" sort="Yacur, Melissa" uniqKey="Yacur M" first="Melissa" last="Yacur">Melissa Yacur</name>
<affiliation><nlm:affiliation>Penn State Health, Hershey, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Malhotra, Mansi" sort="Malhotra, Mansi" uniqKey="Malhotra M" first="Mansi" last="Malhotra">Mansi Malhotra</name>
<affiliation><nlm:affiliation>Tufts Medical Center, Boston, MA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Svoboda, Jakub" sort="Svoboda, Jakub" uniqKey="Svoboda J" first="Jakub" last="Svoboda">Jakub Svoboda</name>
<affiliation><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Furman, Richard R" sort="Furman, Richard R" uniqKey="Furman R" first="Richard R" last="Furman">Richard R. Furman</name>
<affiliation><nlm:affiliation>New York Presbyterian & Weill Cornell, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Nabhan, Chadi" sort="Nabhan, Chadi" uniqKey="Nabhan C" first="Chadi" last="Nabhan">Chadi Nabhan</name>
<affiliation><nlm:affiliation>Cardinal Health, Dublin, OH, USA.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Haematologica</title>
<idno type="eISSN">1592-8721</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Aged, 80 and over (MeSH)</term>
<term>Antineoplastic Agents (administration & dosage)</term>
<term>Antineoplastic Agents (adverse effects)</term>
<term>Antineoplastic Agents (therapeutic use)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Bridged Bicyclo Compounds, Heterocyclic (administration & dosage)</term>
<term>Bridged Bicyclo Compounds, Heterocyclic (adverse effects)</term>
<term>Bridged Bicyclo Compounds, Heterocyclic (therapeutic use)</term>
<term>Disease Management (MeSH)</term>
<term>Drug Resistance, Neoplasm (MeSH)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Leukemia, Lymphocytic, Chronic, B-Cell (diagnosis)</term>
<term>Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy)</term>
<term>Leukemia, Lymphocytic, Chronic, B-Cell (genetics)</term>
<term>Leukemia, Lymphocytic, Chronic, B-Cell (mortality)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Recurrence (MeSH)</term>
<term>Sulfonamides (administration & dosage)</term>
<term>Sulfonamides (adverse effects)</term>
<term>Sulfonamides (therapeutic use)</term>
<term>Survival Analysis (MeSH)</term>
<term>Treatment Outcome (MeSH)</term>
<term>Tumor Lysis Syndrome (etiology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Agents</term>
<term>Bridged Bicyclo Compounds, Heterocyclic</term>
<term>Sulfonamides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents</term>
<term>Bridged Bicyclo Compounds, Heterocyclic</term>
<term>Sulfonamides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term>
<term>Bridged Bicyclo Compounds, Heterocyclic</term>
<term>Sulfonamides</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Leukemia, Lymphocytic, Chronic, B-Cell</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Leukemia, Lymphocytic, Chronic, B-Cell</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Tumor Lysis Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Leukemia, Lymphocytic, Chronic, B-Cell</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Leukemia, Lymphocytic, Chronic, B-Cell</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Disease Management</term>
<term>Drug Resistance, Neoplasm</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Recurrence</term>
<term>Survival Analysis</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia treated with venetoclax to describe outcomes, toxicities, and treatment selection following venetoclax discontinuation. A total of 141 chronic lymphocytic leukemia patients were included (98% relapsed/refractory). Median age at venetoclax initiation was 67 years (range 37-91), median prior therapies was 3 (0-11), 81% unmutated <i>IGHV</i>
, 45% del(17p), and 26.8% complex karyotype (≥ 3 abnormalities). Prior to venetoclax initiation, 89% received a B-cell receptor antagonist. For tumor lysis syndrome prophylaxis, 93% received allopurinol, 92% normal saline, and 45% rasburicase. Dose escalation to the maximum recommended dose of 400 mg daily was achieved in 85% of patients. Adverse events of interest included neutropenia in 47.4%, thrombocytopenia in 36%, tumor lysis syndrome in 13.4%, neutropenic fever in 11.6%, and diarrhea in 7.3%. The overall response rate to venetoclax was 72% (19.4% complete remission). With a median follow up of 7 months, median progression free survival and overall survival for the entire cohort have not been reached. To date, 41 venetoclax treated patients have discontinued therapy and 24 have received a subsequent therapy, most commonly ibrutinib. In the largest clinical experience of venetoclax-treated chronic lymphocytic leukemia patients, the majority successfully completed and maintained a maximum recommended dose. Response rates and duration of response appear comparable to clinical trial data. Venetoclax was active in patients with mutations known to confer ibrutinib resistance. Optimal sequencing of newer chronic lymphocytic leukemia therapies requires further study.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29880613</PMID>
<DateCompleted><Year>2019</Year>
<Month>09</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>08</Month>
<Day>27</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1592-8721</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>103</Volume>
<Issue>9</Issue>
<PubDate><Year>2018</Year>
<Month>09</Month>
</PubDate>
</JournalIssue>
<Title>Haematologica</Title>
<ISOAbbreviation>Haematologica</ISOAbbreviation>
</Journal>
<ArticleTitle>Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.</ArticleTitle>
<Pagination><MedlinePgn>1511-1517</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3324/haematol.2018.193615</ELocationID>
<Abstract><AbstractText>Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia treated with venetoclax to describe outcomes, toxicities, and treatment selection following venetoclax discontinuation. A total of 141 chronic lymphocytic leukemia patients were included (98% relapsed/refractory). Median age at venetoclax initiation was 67 years (range 37-91), median prior therapies was 3 (0-11), 81% unmutated <i>IGHV</i>
, 45% del(17p), and 26.8% complex karyotype (≥ 3 abnormalities). Prior to venetoclax initiation, 89% received a B-cell receptor antagonist. For tumor lysis syndrome prophylaxis, 93% received allopurinol, 92% normal saline, and 45% rasburicase. Dose escalation to the maximum recommended dose of 400 mg daily was achieved in 85% of patients. Adverse events of interest included neutropenia in 47.4%, thrombocytopenia in 36%, tumor lysis syndrome in 13.4%, neutropenic fever in 11.6%, and diarrhea in 7.3%. The overall response rate to venetoclax was 72% (19.4% complete remission). With a median follow up of 7 months, median progression free survival and overall survival for the entire cohort have not been reached. To date, 41 venetoclax treated patients have discontinued therapy and 24 have received a subsequent therapy, most commonly ibrutinib. In the largest clinical experience of venetoclax-treated chronic lymphocytic leukemia patients, the majority successfully completed and maintained a maximum recommended dose. Response rates and duration of response appear comparable to clinical trial data. Venetoclax was active in patients with mutations known to confer ibrutinib resistance. Optimal sequencing of newer chronic lymphocytic leukemia therapies requires further study.</AbstractText>
<CopyrightInformation>Copyright© 2018 Ferrata Storti Foundation.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mato</LastName>
<ForeName>Anthony R</ForeName>
<Initials>AR</Initials>
<AffiliationInfo><Affiliation>CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA matoa@mskcc.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Thompson</LastName>
<ForeName>Meghan</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Allan</LastName>
<ForeName>John N</ForeName>
<Initials>JN</Initials>
<AffiliationInfo><Affiliation>New York Presbyterian & Weill Cornell, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Brander</LastName>
<ForeName>Danielle M</ForeName>
<Initials>DM</Initials>
<AffiliationInfo><Affiliation>Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pagel</LastName>
<ForeName>John M</ForeName>
<Initials>JM</Initials>
<AffiliationInfo><Affiliation>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ujjani</LastName>
<ForeName>Chaitra S</ForeName>
<Initials>CS</Initials>
<AffiliationInfo><Affiliation>Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hill</LastName>
<ForeName>Brian T</ForeName>
<Initials>BT</Initials>
<AffiliationInfo><Affiliation>Taussig Cancer Institute, Cleveland Clinic Foundation, OH, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lamanna</LastName>
<ForeName>Nicole</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Columbia University Medical Center, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lansigan</LastName>
<ForeName>Frederick</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jacobs</LastName>
<ForeName>Ryan</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shadman</LastName>
<ForeName>Mazyar</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>University of Washington/Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, WA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Skarbnik</LastName>
<ForeName>Alan P</ForeName>
<Initials>AP</Initials>
<AffiliationInfo><Affiliation>John Theurer Cancer Center, Hackensack Meridian Health, NJ, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pu</LastName>
<ForeName>Jeffrey J</ForeName>
<Initials>JJ</Initials>
<AffiliationInfo><Affiliation>Penn State Health, Hershey, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Barr</LastName>
<ForeName>Paul M</ForeName>
<Initials>PM</Initials>
<AffiliationInfo><Affiliation>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sehgal</LastName>
<ForeName>Alison R</ForeName>
<Initials>AR</Initials>
<AffiliationInfo><Affiliation>University of Pittsburgh Medical Center, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cheson</LastName>
<ForeName>Bruce D</ForeName>
<Initials>BD</Initials>
<AffiliationInfo><Affiliation>Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zent</LastName>
<ForeName>Clive S</ForeName>
<Initials>CS</Initials>
<AffiliationInfo><Affiliation>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tuncer</LastName>
<ForeName>Hande H</ForeName>
<Initials>HH</Initials>
<AffiliationInfo><Affiliation>Tufts Medical Center, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schuster</LastName>
<ForeName>Stephen J</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo><Affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pickens</LastName>
<ForeName>Peter V</ForeName>
<Initials>PV</Initials>
<AffiliationInfo><Affiliation>Abington Hem. Onc. Assoc., Inc., Willow Grove, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shah</LastName>
<ForeName>Nirav N</ForeName>
<Initials>NN</Initials>
<AffiliationInfo><Affiliation>Division of Hematology & Oncology, Medical College of Wisconsin, Brookfield, WI, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Goy</LastName>
<ForeName>Andre</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>John Theurer Cancer Center, Hackensack Meridian Health, NJ, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Winter</LastName>
<ForeName>Allison M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo><Affiliation>Taussig Cancer Institute, Cleveland Clinic Foundation, OH, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Garcia</LastName>
<ForeName>Christine</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>University of Pittsburgh Medical Center, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kennard</LastName>
<ForeName>Kaitlin</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Isaac</LastName>
<ForeName>Krista</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Internal Medicine, Lankenau Medical Center, Wynnewood, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dorsey</LastName>
<ForeName>Colleen</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gashonia</LastName>
<ForeName>Lisa M</ForeName>
<Initials>LM</Initials>
<AffiliationInfo><Affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Singavi</LastName>
<ForeName>Arun K</ForeName>
<Initials>AK</Initials>
<AffiliationInfo><Affiliation>Division of Hematology & Oncology, Medical College of Wisconsin, Brookfield, WI, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Roeker</LastName>
<ForeName>Lindsey E</ForeName>
<Initials>LE</Initials>
<AffiliationInfo><Affiliation>CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zelenetz</LastName>
<ForeName>Andrew</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Williams</LastName>
<ForeName>Annalynn</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Howlett</LastName>
<ForeName>Christina</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>John Theurer Cancer Center, Hackensack Meridian Health, NJ, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Weissbrot</LastName>
<ForeName>Hanna</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Columbia University Medical Center, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ali</LastName>
<ForeName>Naveed</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Abington Hem. Onc. Assoc., Inc., Willow Grove, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Khajavian</LastName>
<ForeName>Sirin</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>University of Washington/Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, WA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sitlinger</LastName>
<ForeName>Andrea</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tranchito</LastName>
<ForeName>Eve</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Taussig Cancer Institute, Cleveland Clinic Foundation, OH, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rhodes</LastName>
<ForeName>Joanna</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Felsenfeld</LastName>
<ForeName>Joshua</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>New York Presbyterian & Weill Cornell, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bailey</LastName>
<ForeName>Neil</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Patel</LastName>
<ForeName>Bhavisha</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Washington Hospital Center, DC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Burns</LastName>
<ForeName>Timothy F</ForeName>
<Initials>TF</Initials>
<AffiliationInfo><Affiliation>Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yacur</LastName>
<ForeName>Melissa</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Penn State Health, Hershey, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Malhotra</LastName>
<ForeName>Mansi</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Tufts Medical Center, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Svoboda</LastName>
<ForeName>Jakub</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Furman</LastName>
<ForeName>Richard R</ForeName>
<Initials>RR</Initials>
<AffiliationInfo><Affiliation>New York Presbyterian & Weill Cornell, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nabhan</LastName>
<ForeName>Chadi</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Cardinal Health, Dublin, OH, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>T32 HL007057</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2018</Year>
<Month>06</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Italy</Country>
<MedlineTA>Haematologica</MedlineTA>
<NlmUniqueID>0417435</NlmUniqueID>
<ISSNLinking>0390-6078</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019086">Bridged Bicyclo Compounds, Heterocyclic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>N54AIC43PW</RegistryNumber>
<NameOfSubstance UI="C579720">venetoclax</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019086" MajorTopicYN="N">Bridged Bicyclo Compounds, Heterocyclic</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019468" MajorTopicYN="N">Disease Management</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015451" MajorTopicYN="N">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015275" MajorTopicYN="N">Tumor Lysis Syndrome</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year>
<Month>03</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2018</Year>
<Month>06</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>6</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>9</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>6</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">29880613</ArticleId>
<ArticleId IdType="pii">haematol.2018.193615</ArticleId>
<ArticleId IdType="doi">10.3324/haematol.2018.193615</ArticleId>
<ArticleId IdType="pmc">PMC6119152</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>N Engl J Med. 2016 Jan 28;374(4):311-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26639348</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Oncol. 2017 May 1;28(5):1050-1056</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28453705</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Haematologica. 2016 Dec;101(12):1563-1572</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27756834</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Oncol. 2018 Jan;19(1):65-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29246803</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2008 Jun 15;111(12):5446-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18216293</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Oncol. 2016 Jun;17(6):768-778</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27178240</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Haematologica. 2018 May;103(5):874-879</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29419429</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 1998 Dec 5;317(7172):1572</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9836663</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2011 May 12;364(19):1844-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21561350</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2018 Mar 22;378(12):1107-1120</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29562156</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2017 Jun 22;129(25):3362-3370</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28473407</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2016 Nov 3;128(18):2199-2205</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27601462</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2018 Apr 12;131(15):1704-1711</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29305552</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/WillowV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000701 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000701 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    WillowV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:29880613
   |texte=   Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:29880613" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a WillowV1

This area was generated with Dilib version V0.6.37.
Data generation: Tue Nov 17 16:35:40 2020. Site generation: Tue Nov 17 16:39:32 2020

	Serveur d'exploration sur le saule
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le saule

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki